Table 3. Toxicity by patients.
|
UFT 390 mg m−2, 16 pts. |
UFT 300 mg m−2, 66 pts. |
|||
|---|---|---|---|---|
| Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |
| Nausea/vomiting | 12 (75%) | 3 (19%) | 32 (48%) | 9 (14%) |
| Diarrhoea | 4 (25%) | 9 (56%) | 28 (42%) | 14 (21%) |
| Stomatitis | 4 (25%) | 0 | 9 (14%) | 1 (1%) |
| Gastric paina | 3 (19%) | 0 | 5 (8%) | 0 |
| Neutropenia | 3 (19%) | 1 (6%) | 18 (27%) | 2 (3%) |
| Thrombocytopenia | 10 (62%) | 0 | 32 (48%) | 1 (1%) |
| Anaemia | 9 (56%) | 0 | 32 (48%) | 3 (5%) |
| Asthenia | 12 (75%) | 4 (25%) | 25 (38%) | 6 (9%) |
| Sensitive neuropathy | 10 (62%) | 3 (18%) | 39 (59%) | 9 (14%) |
| Transaminases | 6 (37%) | 0 | 22 (33%) | 0 |
a
Gastric pain: Grade 1–2: abated with antacids or H2-blockers. Grade 3–4: intense enough to require withdrawal of UFT.